Stock·NYSE·Consumer Cyclical
Cava Group, Inc. (CAVA)
- Market cap
- $6.91B
- P/E
- 107.55
- Dividend yield
- No dividend
- Street target
- $82.00median of 28 analysts
- 52-week range
- $43.41 $98.79
CAVA stock forecast today
Where CAVA stands today, and what CleaRank Financial AI makes of it.
CAVA at a glance
Cava Group, Inc. (CAVA): Hold, 48/100 on CleaRank's AI score.
- Trend Mixed: the price is above its 50-day but below its 200-day moving average ($55.73 and $71.32).
- Earnings CAVA beat estimates in 5 of its last 8 quarters, yet fell in the first session after 2 of those beats.
- Insiders Insiders sold $291.8M and bought $1.2M over the last 18 months.
- Valuation P/E of 107.5 against 20.8 for the Consumer Cyclical sector: a premium to peers (+417%).
Figures as of November 6, 2026.
CleaRank Financial AI
CleaRank rates Cava Group, Inc. (CAVA) as a Hold, with a model score of 48/100.
The largest boost comes from the analysts' outlook, where 19 of 28 analysts call the stock a buy and the median target is 38.6% above the price. The trend is the largest drag: the price is 17.07% below its 200-day average, and the 50-day average is 21.86% below the 200-day. Currently the 50-day average is $55.73 and the 200-day is $71.32. The price rose 26.96% over the past year.
Only on CleaRank
Figures we compute ourselves from CAVA's own price, earnings and insider-filing history. Tap one to see it in context.
CAVA stock price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
1/4Price above its 50-day average ›
The price of $59.15 is 6.1% above the 50-day simple moving average of $55.73.Price below its 200-day average ›
The price is 17.1% below the 200-day simple moving average of $71.32.50-day average below the 200-day ›
The 50-day average ($55.73) is 21.9% below the 200-day average ($71.32), the arrangement of a falling longer-term trend.In the lower half of its 52-week range ›
The price sits at 28% of its 52-week range, between $43.41 and $98.79.
CAVA share price
Pick a period: each tab shows how far CAVA has moved over it, to the last close.
Today's trading
Where CAVA sits inside today's range and its 52-week range.
CAVA fundamentals and valuation
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
2/4P/E above the sector median ›
The trailing P/E of 107.55 is 417.0% above the Consumer Cyclical median of 20.8.P/S above the sector median ›
The price-to-sales ratio of 4.80 is 152.9% above the sector median of 1.9.Profitable over the last 12 months ›
Net income over the last 12 months was $64.7M on revenue of $1.4B, a net margin of 4.5%.Beat estimates in most recent reports ›
CAVA beat the EPS estimate in 5 of its last 8 reports.
Key statistics
The headline figures for CAVA.
As of November 6, 2026, CAVA trades at $59.15, with a market value of $6.91B and a P/E ratio of 107.55.
What the numbers say
CleaRank Financial AI's reading of CAVA's valuation, growth and risks.
CAVA trades at 107.55 times trailing earnings, a multiple that is 417.0% above the Consumer Cyclical median of 20.8. The peer comparison on this page calls that a premium to peers. Measured on sales, its P/S of 4.80 is 152.6% above the sector median of 1.9.
Margins stand at a net margin of 4.50% and an operating margin of 4.65%. Its return on equity is 7.95%, below the sector median of 12.4%. Debt-to-equity of 0.63 rounds out the fundamentals.
CAVA came up short in its November 4, 2026 report, with EPS of $0.11 against an estimate of $0.12, a miss of 8.33%. Investors reacted accordingly, and the stock dropped 3.18% in the first session after the release.
Over its last 8 reports, CAVA topped the estimate 5 times, but beats have not guaranteed gains: the stock fell in the first session after 2 of them. Earlier, the stock rose 26.36% after the February 24, 2026 report, a beat of 33.33%. Looking ahead, analysts expect EPS of $0.52 this fiscal year (a decline of 3.0%) and $0.74 the year after (growth of 42.3%).
Day-to-day volatility is the first thing to plan around: CAVA has moved 3.29% on a typical session; measured against the S&P 500, its beta is 1.76. Valuation leaves less margin for error: the P/E of 107.55 is 417.0% above the sector median, a premium to peers. The price is 40.13% below its 52-week high of $98.79.
CAVA against the Consumer Cyclical sector
How CAVA compares with the median Consumer Cyclical stock CleaRank tracks.
Price to earnings vs sector: CAVA trades at a significant premium to sector peers (+417% against the sector median P/E). Investors are paying more for each dollar of earnings than for the typical stock in the sector.
Return vs SPY: Since May 28, 2025, CAVA has lost 27.8% against a gain of 25.1% for SPY.
Performance against SPY
CAVA and the S&P 500 (SPY) over the same days.
Revenue and earnings
How much CAVA sells, and how much of it becomes profit.
The quarterly bars end with Q1 '26 (the quarter to March 31, 2026); CAVA reported again on November 4, 2026, and that quarter is not in our statement data yet. The 12-month figures come from the statistics feed and may include it.
Revenue growth: Revenue grew 22.4% in FY2025 to $1.2B, from $964M a year earlier.
Profit margin: The net margin was 5.4% in FY2025, down from 13.5% the year before.
Profitable: CAVA earned $63.7M in FY2025.
Earnings reality check
Did CAVA beat what analysts expected, and how did the stock react?
Earnings record: CAVA beat the analyst estimate in 5 of the last 8 quarters.
Market reaction: The stock fell in the first session after 2 of those 5 beats, so a beat has not been enough on its own.
| Report | Estimate | Actual | Surprise | First session | 5 sessions |
|---|---|---|---|---|---|
| Nov 4, 2026after close | $0.12 | $0.11 | -8.33% | -3.18% | - |
| Aug 11, 2026after close | $0.18 | $0.19 | +5.56% | +14.24% | +12.22% |
| May 19, 2026after close | $0.17 | $0.20 | +17.65% | +3.08% | +5.22% |
| Feb 24, 2026after close | $0.03 | $0.04 | +33.33% | +26.36% | +13.67% |
| Nov 4, 2025after close | $0.12 | $0.12 | +0.00% | -2.57% | -4.74% |
| Aug 12, 2025after close | $0.14 | $0.16 | +14.29% | -16.63% | -18.99% |
| May 15, 2025after close | $0.15 | $0.22 | +46.67% | -2.27% | -14.84% |
| Feb 25, 2025after close | $0.06 | $0.05 | -16.67% | -0.34% | -13.14% |
As of November 6, 2026, CAVA has beaten the analyst EPS estimate in 5 of its last 8 reported quarters and fell in the first trading session after 2 of those beats; its latest report, on November 4, 2026, came in 8.33% below the estimate and the stock moved -3.18% in the first session.
The first session is the first full trading day on the news: the report day itself for a report before the open, the next day for one after the close. Surprise is actual EPS against the consensus estimate.
CAVA AI analysis and technical indicators
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 55.3, in neutral territory.RSI above 50 ›
An RSI of 55.3 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank Financial AI analysis of CAVA
The score, the reasoning behind it, and what could move the price next.
Cava Group, Inc. (CAVA) is caught between its two moving averages. At $59.15, the stock sits 17.07% below its 200-day average of $71.32 but 6.13% above its 50-day average of $55.73. Sitting at 28% of its 52-week range, the price is 36.26% above the 52-week low of $43.41. The 50-day average is 21.86% below the 200-day, a sign that the recent recovery has yet to climb up to the longer-run averages.
The three-month move runs against the others: the price rose 13.60% over the past month, fell 5.24% over the past three months and rose 26.96% over the past year. On momentum, the 14-day RSI reads 55.3, in the neutral zone, with the MACD line positive.
Analyst upgrade ›
Melius Research upgraded it to Buy from Hold on October 8, 2026.
Source: Analyst action, Melius Research, October 8, 2026
Earnings miss ›
The November 4, 2026 report missed the EPS estimate by 8.33%, and the share price fell 3.18% in the first session after it.
Source: Earnings report, November 4, 2026
Rating reaffirmed ›
Mizuho kept its Neutral rating on October 30, 2026.
Source: Analyst action, Mizuho, October 30, 2026
- Two levels matter most here: the 200-day SMA at $71.32, which sits above the price, and the 20-day EMA at $57.25, which sits below it.
- The 14-day RSI is 55.3, in the neutral zone, and the MACD line is positive. Momentum is only considered stretched when readings climb above 70 or drop below 30.
- After the November 4, 2026 report the share price fell 3.18% in the first session; CAVA beat estimates in 5 of the last 8 reports.
CAVA is giving mixed signals. The price is above the 50-day average of $55.73 but under the 200-day average of $71.32. Should the price close above the 200-day, both signals would point up; a close below the 50-day would point both down. For now, the 20-day EMA at $57.25 lies beneath the price, and the 200-day SMA at $71.32 sits above it.
Technical indicators
Momentum and trend for CAVA, from its daily closes.
As of November 6, 2026, with CAVA at $59.15, its 14-day RSI is 55.3 (neutral territory), its 50-day simple moving average is $55.73 and its 200-day is $71.32.
Calculated by CleaRank on daily closes as of November 6, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26). How we calculate these
What CAVA moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of November 6, 2026, CAVA's 1-year correlation of daily returns is +0.44 with S&P 500 (SPY), +0.40 with Nasdaq 100 (QQQ), +0.21 with Bitcoin (BTC) and +0.08 with gold (XAU).
CAVA price target and analyst forecast
The analysts' target range and how their ratings split.
Analysts checks
3/3Most analysts rate it a buy ›
19 of 28 analysts rate it a buy or strong buy, 8 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $82.00 is 38.6% above the price.Larger share of buy ratings than three months ago ›
19 of 28 rate it a buy now, against 18 of 28 three months ago.
CAVA Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Oct 30, 2026 | Mizuho | Maintains | Neutral |
| Oct 23, 2026 | Keybanc | Maintains | Overweight |
| Oct 22, 2026 | UBS | Maintains | Buy |
| Oct 22, 2026 | Citigroup | Maintains | Neutral |
| Oct 21, 2026 | TD Cowen | Maintains | Buy |
| Oct 8, 2026 | Melius Research | Upgrade | Buy |
As of November 6, 2026, 28 Wall Street analysts cover CAVA: 19 rate it a buy or strong buy, 8 a hold and 1 a sell or strong sell. Their 12-month price targets range from $18.00 to $110.00. The median CAVA price target is $82.00, 38.6% above the price of $59.15.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
CAVA risk and volatility
How much it moves day to day, and how it stacks up against similar assets.
Risk profile
How much CAVA tends to move, against the market and on its own.
CAVA price history and drawdowns
CAVA's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Typical daily move of 2% or more ›
A typical daily move is 3.29% (the standard deviation of the last 30 daily returns).Not yet recovered from its worst fall ›
The worst fall was 71.1%, from December 2024 to November 2025; the price is still 60.8% below that peak.Most 1-year holds ended higher ›
51% of 1-year holding periods in the last 3 years ended with a gain.Trailed the S&P 500 since July 2023 ›
$10,000 invested in July 2023 is now worth $14,982, against $17,238 in the S&P 500 (SPY).
CAVA Drawdowns & Recovery
As of November 6, 2026, CAVA's worst peak-to-trough fall over the period since July 2023 was -71.1% (December 2024 to November 2025); it is still 60.8% below that peak, and 51% of 1-year holding periods ended with a gain.
From weekly closing values. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into CAVA in July 2023 is worth now, against the same amount in the S&P 500.
Against the market: CAVA trailed the S&P 500 over this period: $14,982 against $17,238.
A $10,000 investment in CAVA in July 2023 would be worth about $14,982 today, compared with about $17,238 for the same investment in the S&P 500 benchmark with its dividends reinvested.
Seasonal patterns
Which calendar months have been kind to CAVA, and which have not.
Strongest month, January: an average of +11.28%, up in 3 of 3 years.
Weakest month, September: an average of -12.69%, up in 1 of 4 years.
This month, November: has averaged +0.74%, up in 2 of 3 years. Past seasonality does not repeat on schedule.
Across 4 calendar years of history, CAVA's strongest calendar month has been January (average +11.28%, up in 3 of 3 years) and its weakest September (average -12.69%, up in 1 of 4 years).
Average return for each calendar month across 4 calendar years of history, from weekly closing prices.
CAVA stock price prediction 2029
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in CAVA, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 3-year Monte Carlo simulation, based on 3.3 years of price history, projects that a $10,000 investment in CAVA today could grow to about $12,731 by 2029 in the base case, with a 90th-percentile outcome near $38,628 and a 10th-percentile outcome around $4,196. Projections are statistical simulations, not guarantees.
CAVA Stock Price Prediction 2029: Simulated Scenarios
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $75.31 for CAVA by 2029 in the base case, from $59.15 today (1.3x over 3 years). The 10th-percentile path ends near $24.82. These are outcomes of a Monte Carlo simulation run on CAVA's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $33.78 | $64.11 | $122 | |
| 2028 | $28.07 | $69.48 | $172 | |
| 2029 | $24.82 | $75.31 | $228 |
Method: a lognormal simulation of CAVA's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles. How the simulation works
CAVA insider trading
What the people running the company have bought and sold.
CAVA insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Net insider selling: Insiders bought $1.2M on the open market and sold $291.8M.
As of November 6, 2026, CAVA insiders reported 36 open-market sales worth $291.8M and 7 open-market purchases worth $1.2M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Joseph John Kadow
Officer
|
Buy | 1.0K | $50.0K |
| Sep 9, 2026 | Theodoros Xenohristos
Officer and Director
|
Grant | 16.5K | - |
| Aug 31, 2026 | Douglas W Thompson
Chief Operating Officer
|
Buy | 6.5K | $432.4K |
| Aug 13, 2026 | Amiee Lynn Thomas
Director
|
Grant | 1.8K | - |
| Jun 22, 2026 | Philippe Amouyal
Director
|
Grant | 1.9K | - |
| Jun 22, 2026 | David Bosserman
Director
|
Grant | 1.9K | - |
| Jun 22, 2026 | Benjamin Felt
Director
|
Grant | 1.9K | - |
| Jun 22, 2026 | Ronald M Shaich
Director
|
Grant | 1.9K | - |
| Jun 22, 2026 | Lauri M. Shanahan
Director
|
Grant | 1.9K | - |
| Jun 22, 2026 | James D White
Director
|
Grant | 1.9K | - |
| Jun 18, 2026 | Karen Kochevar
Director
|
Sell | 10.0K | $900.0K |
| Jun 18, 2026 | Karen Kochevar
Director
|
Option | 10.0K | $67.1K |
| Jun 17, 2026 | Kelly Costanza
Officer
|
Sell | 15.4K | $1.4M |
| Jun 15, 2026 | Participations S.a.r.l. Artal
Unknown
|
Sell | 3.0M | $270.9M |
| Jun 15, 2026 | Brett M Schulman
Chief Executive Officer
|
Sell | 33.2K | $3.0M |
| Jun 15, 2026 | Patricia K Tolivar
Chief Financial Officer
|
Sell | 5.0K | $444.4K |
| Jun 15, 2026 | Theodoros Xenohristos
Officer and Director
|
Sell | 3.3K | $290.8K |
| Jun 15, 2026 | Adam David Phillips
Officer
|
Sell | 757 | $67.7K |
| Jun 15, 2026 | Patricia K Tolivar
Chief Financial Officer
|
Grant | 283 | $25.3K |
| Jun 12, 2026 | Adam David Phillips
Officer
|
Sell | 4.7K | $423.1K |
| Jun 12, 2026 | Adam David Phillips
Officer
|
Option | 2.8K | $60.8K |
| Jun 3, 2026 | Joseph John Kadow
Officer
|
Buy | 1.0K | $70.0K |
| May 29, 2026 | Joseph John Kadow
Officer
|
Buy | 1.0K | $79.0K |
| May 29, 2026 | Douglas W Thompson
Chief Operating Officer
|
Buy | 2.5K | $194.8K |
| May 26, 2026 | Douglas W Thompson
Chief Operating Officer
|
Buy | 4.0K | $317.8K |
| May 21, 2026 | Kelly Costanza
Officer
|
Sell | 10.0K | $799.5K |
| May 21, 2026 | Adam David Phillips
Officer
|
Sell | 5.2K | $399.7K |
| May 21, 2026 | Adam David Phillips
Officer
|
Option | 5.2K | $49.6K |
| May 11, 2026 | Theodoros Xenohristos
Officer and Director
|
Sell | 9.0K | $721.3K |
| Mar 5, 2026 | Kenneth Robert Bertram
Officer
|
Sell | 15.0K | $1.2M |
| Feb 26, 2026 | Kelly Costanza
Officer
|
Sell | 31.8K | $2.7M |
| Feb 26, 2026 | Adam David Phillips
Officer
|
Sell | 2.0K | $171.1K |
| Feb 26, 2026 | Kenneth Robert Bertram
Officer
|
Grant | 3.8K | - |
| Feb 26, 2026 | Kelly Costanza
Officer
|
Option | 31.8K | $214.7K |
| Feb 26, 2026 | Kelly Costanza
Officer
|
Grant | 4.7K | - |
| Feb 26, 2026 | Adam David Phillips
Officer
|
Grant | 1.1K | - |
| Feb 26, 2026 | Brett M Schulman
Chief Executive Officer
|
Grant | 29.1K | - |
| Feb 26, 2026 | Patricia K Tolivar
Chief Financial Officer
|
Grant | 8.0K | - |
| Feb 26, 2026 | Theodoros Xenohristos
Officer and Director
|
Grant | 4.7K | - |
| Jan 27, 2026 | Brett M Schulman
Chief Executive Officer
|
Sell | 4.5K | $282.3K |
| Jan 27, 2026 | Patricia K Tolivar
Chief Financial Officer
|
Sell | 2.4K | $149.4K |
| Jan 27, 2026 | Kelly Costanza
Officer
|
Sell | 1.7K | $106.1K |
| Jan 27, 2026 | Theodoros Xenohristos
Officer and Director
|
Sell | 1.0K | $64.6K |
| Jan 27, 2026 | Kenneth Robert Bertram
Officer
|
Sell | 994 | $61.8K |
| Jan 27, 2026 | Adam David Phillips
Officer
|
Sell | 774 | $48.1K |
| Jan 21, 2026 | Brett M Schulman
Chief Executive Officer
|
Sell | 21.7K | $1.5M |
| Jan 21, 2026 | Patricia K Tolivar
Chief Financial Officer
|
Sell | 2.2K | $148.6K |
| Jan 21, 2026 | Kelly Costanza
Officer
|
Sell | 1.7K | $114.7K |
| Jan 21, 2026 | Kenneth Robert Bertram
Officer
|
Sell | 1.1K | $72.4K |
| Jan 21, 2026 | Theodoros Xenohristos
Officer and Director
|
Sell | 965 | $65.1K |
| Dec 15, 2025 | Kenneth Robert Bertram
Officer
|
Grant | 47 | $2.1K |
| Nov 26, 2025 | Kenneth Robert Bertram
Officer
|
Sell | 3.8K | $192.1K |
| Nov 12, 2025 | Brett M Schulman
Chief Executive Officer
|
Buy | 150 | $7.3K |
| Nov 10, 2025 | Brett M Schulman
Chief Executive Officer
|
Option | 36.7K | $212.4K |
| Sep 29, 2025 | Kenneth Robert Bertram
Officer
|
Sell | 3.8K | $222.0K |
| Sep 18, 2025 | Theodoros Xenohristos
Officer and Director
|
Grant | 16.0K | - |
| Jun 20, 2025 | Philippe Amouyal
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | David Bosserman
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | Benjamin Felt
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | Karen Kochevar
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | Ronald M Shaich
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | Lauri M. Shanahan
Director
|
Grant | 1.8K | - |
| Jun 20, 2025 | James D White
Director
|
Grant | 1.8K | - |
| Jun 16, 2025 | Brett M Schulman
Chief Executive Officer
|
Sell | 31.9K | $2.4M |
| Jun 16, 2025 | Patricia K Tolivar
Chief Financial Officer
|
Sell | 4.8K | $364.1K |
| Jun 16, 2025 | Theodoros Xenohristos
Officer and Director
|
Sell | 3.1K | $230.1K |
| Jun 16, 2025 | Jennifer Somers
Officer
|
Sell | 2.9K | $215.0K |
| Jun 16, 2025 | Kelly Costanza
Officer
|
Sell | 2.8K | $210.4K |
| Jun 16, 2025 | Kenneth Robert Bertram
Officer
|
Sell | 2.2K | $165.2K |
| Jun 16, 2025 | Adam David Phillips
Officer
|
Sell | 739 | $55.5K |
| Jun 16, 2025 | Kenneth Robert Bertram
Officer
|
Grant | 169 | $10.7K |
| Jun 16, 2025 | Adam David Phillips
Officer
|
Grant | 146 | $9.3K |
| Jun 16, 2025 | Jennifer Somers
Chief Operating Officer
|
Grant | 133 | $8.4K |
| Jun 16, 2025 | Patricia K Tolivar
Chief Financial Officer
|
Grant | 197 | $12.5K |
| May 21, 2025 | Kelly Costanza
Officer
|
Sell | 10.2K | $887.4K |
| May 9, 2025 | Theodoros Xenohristos
Officer and Director
|
Sell | 9.3K | $887.0K |
Source: TwelveData, from SEC Form 4 filings
CAVA stock forecast: questions people ask
Answered from the figures on this page, as of November 6, 2026.